Amélie Boichard - Search Results

Year	Number of Results
2014	3
2016	3
2017	3
2018	5
2019	2
2020	8
2021	2
2022	2
2023	0

1

New therapeutic approaches to overcoming resistant EGFR exon 20 alterations.

Li AM, Boichard A, Felip E, Kurzrock R. Li AM, et al. Among authors: boichard a. Crit Rev Oncol Hematol. 2020 Jul;151:102990. doi: 10.1016/j.critrevonc.2020.102990. Epub 2020 May 20. Crit Rev Oncol Hematol. 2020. PMID: 32485428 Free PMC article. Review.

2

Genomes in the clinic: the Gustave Roussy Cancer Center experience.

Lacroix L, Boichard A, André F, Soria JC. Lacroix L, et al. Among authors: boichard a. Curr Opin Genet Dev. 2014 Feb;24:99-106. doi: 10.1016/j.gde.2013.11.013. Epub 2014 Feb 26. Curr Opin Genet Dev. 2014. PMID: 24583392 Review.

3

High tumor amplification burden is associated with TP53 mutations in the pan-cancer setting.

Joshi RS, Boichard A, Adashek JJ, Kurzrock R. Joshi RS, et al. Among authors: boichard a. Cancer Biol Ther. 2022 Dec 31;23(1):1-6. doi: 10.1080/15384047.2022.2128608. Cancer Biol Ther. 2022. PMID: 36171565 Free PMC article.

4

Variable Mutation Expression in Human Cancers: A "Hide-and-Seek" Mechanism Linked to Differential MHC-I Presentation Dynamics.

Boichard A, Kurzrock R. Boichard A, et al. Mol Cancer Ther. 2022 Jul 5;21(7):1219-1226. doi: 10.1158/1535-7163.MCT-21-0831. Mol Cancer Ther. 2022. PMID: 35545005

5

APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy.

Boichard A, Pham TV, Yeerna H, Goodman A, Tamayo P, Lippman S, Frampton GM, Tsigelny IF, Kurzrock R. Boichard A, et al. Oncoimmunology. 2018 Dec 24;8(3):1550341. doi: 10.1080/2162402X.2018.1550341. eCollection 2019. Oncoimmunology. 2018. PMID: 30723579 Free PMC article.

6

Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing.

Boichard A, Wagner MJ, Kurzrock R. Boichard A, et al. Genome Med. 2020 Jul 9;12(1):61. doi: 10.1186/s13073-020-00753-2. Genome Med. 2020. PMID: 32646514 Free PMC article.

7

Therapeutic implications of cancer gene amplifications without mRNA overexpression: silence may not be golden.

Boichard A, Lippman SM, Kurzrock R. Boichard A, et al. J Hematol Oncol. 2021 Dec 2;14(1):201. doi: 10.1186/s13045-021-01211-1. J Hematol Oncol. 2021. PMID: 34857015 Free PMC article.

8

Mutated TP53 is a marker of increased VEGF expression: analysis of 7,525 pan-cancer tissues.

Li AM, Boichard A, Kurzrock R. Li AM, et al. Among authors: boichard a. Cancer Biol Ther. 2020;21(1):95-100. doi: 10.1080/15384047.2019.1665956. Epub 2019 Sep 29. Cancer Biol Ther. 2020. PMID: 31564192 Free PMC article.

9

Machine learning model to predict oncologic outcomes for drugs in randomized clinical trials.

Schperberg AV, Boichard A, Tsigelny IF, Richard SB, Kurzrock R. Schperberg AV, et al. Among authors: boichard a. Int J Cancer. 2020 Nov 1;147(9):2537-2549. doi: 10.1002/ijc.33240. Epub 2020 Aug 19. Int J Cancer. 2020. PMID: 32745254 Free article.

10

Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy.

Pham TV, Boichard A, Goodman A, Riviere P, Yeerna H, Tamayo P, Kurzrock R. Pham TV, et al. Among authors: boichard a. Mol Oncol. 2020 Aug;14(8):1680-1694. doi: 10.1002/1878-0261.12748. Epub 2020 Jul 7. Mol Oncol. 2020. PMID: 32530570 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

25 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year